Login to Your Account



Xoma seeks $50M at threshold of pivotal gevokizumab readouts

By Marie Powers
Staff Writer

Monday, December 16, 2013
Awaiting multiple gevokizumab (XOMA 052) data readouts in 2014, including the first Phase III data by midyear, on Friday Xoma Corp. priced a public offering of 9.5 million shares of common stock at $5.25 apiece, seeking to raise $50 million. The Berkeley, Calif.-based company granted underwriters a 30-day option to purchase up to an additional 1.4 million shares, potentially increasing its haul by $7.5 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription